The Dermatology Digest

FEBRUARY 10, 2025

This acquisition strengthens our leadership position and enhances our ability to deliver innovative solutions to customers, with what we believe is a comprehensive portfolio that represents the three pillars of facial aesthetics relax, restore, and regenerate and we will support these offerings with a highly trained and experienced sales force.

Portfolios 36

Portfolios Sales Office Innovations 36

Dermatology Times

OCTOBER 30, 2024

Bob Rhatigan, CEO of Merz Aesthetics, discusses the company’s commitment to advancing the aesthetics industry through strategic partnerships, specialized training, and a growing portfolio of injectables and devices.

Innovations 74

Innovations Portfolios Education Medical 74

The Dermatology Digest

JULY 1, 2024

In addition, the Phase 3 study demonstrated biosimilarity of SB17 to Stelara up to week 28 in terms of efficacy, safety, pharmacokinetics, and immunogenicity, and these data were presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting in March 2024.

Portfolios 74

Portfolios Safety Clinic Injections 74

The Dermatology Digest

AUGUST 12, 2024

As a combined company, we have the opportunity to create a comprehensive portfolio of high-growth products for all stages of life, and we will be committed to investing in education, training, and practice support for aesthetics providers across the United States.” ” Mark J.

Portfolios 69

Portfolios Innovations Marketing Office 69

The Dermatology Digest

MARCH 5, 2024

The Allergan Medical Institute (AMI) team can train aesthetic providers on safe and effective treatments using the Allergan Aesthetics portfolio to address 90% of the face. The post FDA Approves JUVÉDERM VOLUMA XC for Filling Temple Hollows appeared first on The Dermatology Digest.

Portfolios 74

Portfolios Injections Training Facials 74

Southeastern Esthetics Institute

AUGUST 23, 2016

Specific courses for cosmetic lasers, for example, are crucial to add to the esthetics portfolio, in order to showcase added training beyond that of the esthetics fundamentals course. Esthetics practitioners within any advanced setting should obtain certifications underneath their license for each individual advanced procedure.

Esthetician 195

Esthetician Esthetics Document Office 195

Dermatology Times

APRIL 3, 2024

The merger will focus on advancing Oruka’s portfolio of novel biologics for the treatment of chronic skin diseases.

Portfolios 56

Portfolios Treatments 56

The Dermatology Digest

SEPTEMBER 9, 2024

“China has always been a strategic market for Sisram, and the approval of Daxxify serves as a key milestone for bringing Sisram’s high-end injectables portfolio to Mainland China,” says Mr. Liu Yi, Sisram Chairman and Executive Director, in a news release. and Abroad appeared first on The Dermatology Digest.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

JANUARY 2, 2024

Brett Fair Named National Sales Director at Sun Pharma Brett Fair is now Sun Pharma’s National Sales Director for the medical dermatology sales team. Mr. Fair began his career at Allergan and has continued to focus on commercial opportunities in dermatology.

Dermatology 36

Dermatology Sales Skincare Portfolios 36

The Dermatology Digest

JULY 17, 2024

Food and Drug Administration (FDA) has cleared InMode’s Morpheus8 Applicators for the delivery of fractional radiofrequency use in dermatologic skin procedures where coagulation/contraction of soft tissue or hemostasis is needed.

Microneedling 36

Microneedling Portfolios Technology Dermatology 36

The Dermatology Digest

OCTOBER 19, 2024

“Through the acquisition of Suneva Medical assets, Tiger Aesthetics will be able to offer an even larger portfolio of products, partner with more cosmetic providers, and bring Suneva Medical’s expertise in commercializing market defining products to strategic regions globally.”

Medical 36

Medical Portfolios Marketing Facials 36

The Dermatology Digest

APRIL 16, 2024

and the second within its immunology portfolio. The post Biosimilar Update: Fresenius’ Actemra Biosimilar Now Available in the US appeared first on The Dermatology Digest. Tyenne is the first tocilizumab biosimilar with an intravenous and subcutaneous formulation approved by the FDA.

Portfolios 36

Portfolios Dermatology Treatments 36

The Dermatology Digest

SEPTEMBER 30, 2024

market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. The post FDA Nod for Ustekinumab Biosimilar appeared first on The Dermatology Digest. “The FDA approval of Otulfi, Fresenius Kabi’s fourth biosimilar product in the U.S. and worldwide.

Portfolios 36

Portfolios Partnerships Marketing Safety 36

The Dermatology Digest

MARCH 26, 2024

“While NCE status will provide YCANTH with a minimum of five years of protection, we anticipate our full patent portfolio to provide protection from generic competition for the next decade and potentially beyond,” says Ted White, Verrica’s President and Chief Executive Officer, in a news release.

Pharmaceutical 36

Pharmaceutical Portfolios Office Marketing 36

The Dermatology Digest

APRIL 1, 2024

CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases. “We The post Incyte, CMS Partner to Develop Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan, and Southeast Asia appeared first on The Dermatology Digest.

Portfolios 36

Portfolios Injections Innovations Sales 36

The Dermatology Digest

FEBRUARY 20, 2024

In her role of Chief Medical Director, Dr. Obagi will help shape Obagi’s product development, portfolio refinement, research initiatives, and educational programs. “I ” The post Dr. Suzan Obagi Named First-ever Chief Medical Director at Obagi Cosmeceuticals appeared first on The Dermatology Digest.

Medical 36

Medical Medical Grade Skincare Portfolios Skincare 36

The Dermatology Digest

FEBRUARY 28, 2024

A member of the Executive Leadership Team, Steve has an exceptional track record of driving growth through product strategies, portfolio life-cycle management, innovation, and precision tactical execution. ” The post Crown Forms Unified Consumer Skincare Division appeared first on The Dermatology Digest.

Skincare 36

Skincare Portfolios Innovations Office 36

The Dermatology Digest

JULY 5, 2024

million people through Almirall’s dermatology portfolio by 2030. The post Company News: Almirall Launches Updated Sustainability Strategy appeared first on The Dermatology Digest. The overarching goal is to positively impact over 1.8

Sustainability 36

Sustainability Pharmaceutical Portfolios Management 36

The Dermatology Digest

DECEMBER 19, 2023

FILSUVEZ joined the Chiesi portfolio as part of the agreement reached during the acquisition of Amryt Pharma in January 2023. The post FDA Approves FILSUVEZ Topical Gel for Junctional and Dystrophic EB appeared first on The Dermatology Digest.

Portfolios 36

Portfolios Management Clinic Treatments 36

The Dermatology Digest

MARCH 27, 2024

Stern will join the global leadership team and will be responsible for leading the portfolio and brand strategies. The post Alexis (Lexi) Stern Named New CMO at Merz Aesthetics appeared first on The Dermatology Digest. Alexis (Lexi) Stern is Merz Aesthetics’ new Chief Marketing Officer.

Office 36

Office Portfolios Branding Marketing 36

The Dermatology Digest

OCTOBER 1, 2024

We are introducing the first booster in the Hydrafacial portfolio with clinical claims to address dry, dull, dehydrated skin and the signs of aging, which are top skin concerns our providers come across in their treatment rooms,” says BeautyHealth Chief Executive Officer Marla Beck, in a news release.

Hydration 36

Hydration Portfolios Office Surgery 36

The Dermatology Digest

DECEMBER 21, 2023

The two distribution agreements for the Evolysse /Estyme fillers portfolio will grant Evolus the ability to offer filler solutions to cover mid-face, nasolabial folds, and lip indications in Europe plus an eye product line in the U.S.

Marketing 36

Marketing Sales Branding Portfolios 36

The Dermatology Digest

DECEMBER 21, 2023

The two distribution agreements for the Evolysse /Estyme fillers portfolio will grant Evolus the ability to offer filler solutions to cover mid-face, nasolabial folds, and lip indications in Europe plus an eye product line in the U.S.

Marketing 36

Marketing Sales Branding Portfolios 36

The Dermatology Digest

MARCH 5, 2024

The post Topline Phase 1 Trial Results for Apogee’s APG777 in AD “Exceed Expectations” appeared first on The Dermatology Digest. Chief Executive Officer of Apogee, in a news release. .”

Injections 36

Injections Safety Sustainability Clinic 36

The Eco Well Blog

MAY 16, 2022

In Reckitt Benckiser’s Legal department, Meredith developed claims testing protocols, supported NAD challenges, and was responsible for legal approval of all claims and advertising materials for the Health & Hygiene portfolios including Mucinex, Delsym, Air Wick, Lysol, Veet, Clearasil, Durex, among many others.

Legal 52

Legal Pharmaceutical Sun Protection Technology 52

The Eco Well Blog

MAY 8, 2023

She is also an adjunct professor in the Department of Dermatology at the Keck School of Medicine of the University of Southern California. Her area of clinical expertise is in complex medical dermatology, skin cancer, and acne. Carl presented at the Sunscreen E-Summit on behalf of DSM.

Legal 52

Legal Technology Sun Protection Branding 52

The Dermatology Digest

AUGUST 30, 2024

The FDA approval of ACAM2000 for immunization against mpox in high-risk individuals further strengthens and broadens our industry-leading smallpox portfolio, which includes VIGIV and TEMBEXA,” says Joe Papa, president and CEO of Emergent, in a news release.

Portfolios 74

Portfolios Tools Eczema Safety 74

The Dermatology Digest

NOVEMBER 4, 2024

“The MDR CE Mark certification for Estyme , is a critical milestone in our strategic path to expand our product portfolio and reflects our commitment to delivering high-quality gels that adhere to the most rigorous regulatory standards,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release.

Injections 68

Injections Medical Portfolios Branding 68

The Dermatology Digest

APRIL 16, 2025

By pairing this innovative Cold-X technology with the commercial strength weve built with Jeuveau , we are well-positioned to expand our leadership with a differentiated injectable portfolio. The post Evolysse Officially Launches Evolysse Form and Evolysse Smooth appeared first on The Dermatology Digest.

Injections 71

Injections Portfolios Innovations Technology 71

The Dermatology Digest

DECEMBER 5, 2024

Apogee Therapeutics recently hosted its first R&D Day, which featured updates across its entire portfolio. The post Inside the Apogee Pipeline: Company Shares Updates on APG777 and APG990 for AD appeared first on The Dermatology Digest. Stay tuned.

Portfolios 74

Portfolios Dermatitis Sustainability Injections 74

The Dermatology Digest

FEBRUARY 13, 2025

This milestone represents an exciting new chapter in our long-term strategy to expand our portfolio and transition from a single-product company to a multi-product innovator, strengthening our leadership in performance beauty, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. s Evolyssecollection.

Injections 73

Injections Portfolios Innovations Safety 73

The Dermatology Digest

MARCH 7, 2025

Our next phase of growth will be transformative for the industry as we look to create a new category comprised of structural adipose tissue products and a head-to-toe portfolio of diverse treatment options for patients and practices. The Company anticipates the new facility will lead to a doubling of its existing workforce by 2028.

Portfolios 36

Portfolios Technology Medical Management 36

The Dermatology Digest

MARCH 27, 2025

have entered into a collaboration and licensing agreement to develop, manufacture, and commercialize ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for dermatology indications in Japan, with the option to expand the license to include rheumatological and gastrointestinal diseases. Alumis Inc.

Pharmaceutical 36

Pharmaceutical Portfolios Clinic Safety 36

The Dermatology Digest

FEBRUARY 26, 2025

Our clinical trials demonstrate that investigational ZORYVE cream 0.05% effectively relieves the itchy rash of AD in these very young children, with a safe and tolerable profile that dermatology clinicians trust from their experience with our ZORYVE portfolio, adds Frank Watanabe, president and CEO of Arcutis. The post U.S.

Safety 36

Safety Dermatitis Portfolios Clinic 36